GlassScriptPhysician profile
Chandra M Katta
NPI 1831131499
$434.69
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2021: $21.99 · 2022: $206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $187.74 | 2022 | |
| Sunovion Pharmaceuticals INC. | $121.69 | 2019-2022 | |
| Lundbeck LLC | $57.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.20 | 2019 | |
| Shire North American Group INC | $13.86 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Katta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.